Vicryl sutures (polyglactin 910 suture) remain the most widely used absorbable suture material in general surgery worldwide — not because of inertia, but because decades of clinical evidence and consistent performance have earned them that position. For hospital procurement teams, surgical distributors, and laboratory evaluators sourcing absorbable sutures, understanding exactly why Vicryl continues to dominate purchasing decisions is essential to making informed procurement choices. This article provides a clinically grounded, procurement-focused analysis of vicryl suture uses, material science, comparative performance, and documented limitations — everything a professional buyer or distributor needs to know.

A wrong suture size doesn't just complicate a closure — it can compromise healing, increase scarring, and in high-tension anatomical zones, contribute to wound dehiscence. Yet across procurement catalogs and surgical supply chains, suture sizing remains one of the most misunderstood dimensions of suture selection. The USP numbering system is counterintuitive to newcomers, the relationship between gauge and tensile strength is not linear, and the clinical consequences of mismatched sizing vary dramatically by tissue type and patient population.

For decades, the question of absorbable vs non absorbable suture selection has defined the quality of surgical wound outcomes. Despite advances in adhesive technologies and stapling devices, surgical sutures remain the gold standard for wound closure across virtually every surgical specialty. The decision between absorbable sutures and non absorbable suture materials directly influences tissue healing, infection rates, scar quality, and patient recovery timelines.

The landscape of emergency vascular access has shifted dramatically over the past decade. While peripheral intravenous (PIV) cannulation remains the first-line approach, the reality is that up to 10-15% of critically ill patients present with failed peripheral access—a figure that climbs significantly in trauma, cardiac arrest, and hypovolemic shock scenarios. During the COVID-19 pandemic, many hospitals faced unprecedented challenges with difficult venous access in patients under personal protective equipment, leading to increased interest in intraosseous (IO) systems as reliable alternatives.

Intraosseous (IO) infusion has evolved from a last-resort procedure into a standard of care for patients requiring emergency vascular access when peripheral IV fails. Guidelines from resuscitation councils worldwide now recommend IO access within minutes for patients in cardiac arrest, severe shock, or with difficult IV access.